Webinar - Analytical Sciences of Amorphous Solid Dispersions

��ɫAV

Start

Thursday, October 01, 2020 - 16:00

End

Thursday, October 01, 2020 - 16:00

Location: online

Thursday, October��1^st, 2020�� |�� 8 AM (PDT), 11 AM (EDT), 4 PM (GMT)

��

Speakers
João Pereira��-��Team Leader, R&D Analytical Development
Susana Campos��- Group Leader, R&D Analytical Development

��

Amorphous solid dispersions (ASDs) are a promising formulation approach to overcome solubility challenges of poorly water-soluble drugs. However, close monitoring of physical transformations is required to ensure both product’s processability and shelf-life. Detection of low-level physical transformations is important not only to evaluate and forecast product’s stability but also to correlate with product performance.

This webinar will present ��ɫAV’s approach for the characterization of amorphous solid dispersions (ASD) throughout manufacturing process and product shelf-life. In detail, the use of orthogonal solid state and particle characterization techniques, such as XRD, DSC, IR, Raman and SEM, will be presented in a few case studies.

In this webinar you’ll learn:

How to understand and characterize ASD physical stability
What are the most suitable techniques for ASD characterization
Linking processability and physical transformations of ASD

��

Lisbon, Portugal – ��ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ��ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ��ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ��ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ��ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ��ɫAV’s sustainability ambitions. ��ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating. Learn more about Science Based-Targets

News

��ɫAV commitment to setting SBTs in line with the Paris Agreement

��ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

��ɫAV

Browser not supported

Press Room